Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245024 · ClinicalTrials.gov registry record · Phase 1
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00245024 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants.
The verdict
NCT00245024, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac may prevent breast cancer. PURPOSE: This randomized phase I trial is studying the effects of sulindac, to prevent breast cancer, in women at high risk for breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG sulindac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245024
The ClinicalTrials.gov registry entry for NCT00245024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00245024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00245024 about?
NCT00245024 is a clinical study titled "Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac may prevent breast cancer. PURPOSE: This randomized phase I trial is studying the effects of sulindac, to prevent breast cancer, in women at high risk for breast cancer.
What is the current status of trial NCT00245024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2005-11. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00245024?
The interventions under investigation include: laboratory biomarker analysis (OTHER), sulindac (DRUG).
Who is sponsoring clinical trial NCT00245024?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.